Vir Biotechnology Announced Positive Safety Findings from its Ongoing Trials for Chronic HBV
Vir Biotechnology (VIR) announced new data from its ongoing Phase 2 clinical trials of VIR-2218 and ongoing Phase 1 studies of VIR-3434 in patients with chronic hepatitis B virus (HBV) infection.

The results comprised positive safety findings in addition to a reduction in hepatitis . . .